BridgeBio Pharma (BBIO) risk factors, FY2024 10-K

Risks Related to Commercialization

1. 01the prevalence and severity of any side effects or adverse events (“AEs”)
2. 02unforeseen costs and expenses associated with creating an independent commercialization organization
3. 03Our future growth may depend, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties
4. 04the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute
5. 05If we fail to comply with healthcare laws, we could face substantial penalties and our business, operations and financial conditions could be adversely affected
6. 06recruitment for clinical trials. See the section titled, “Business - Government Regulation - Other Regulatory Matters.”
7. 07Failure to comply with health and other personal data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity, and could negatively affect our operating results and business
8. 08Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations
9. 09the availability of capital
10. 10Recent federal legislation and actions by state and local governments may permit reimportation of drugs from foreign countries into the United States, including foreign countries where the drugs are sold at lower prices than in the United States, which could materially adversely affect our operating results
11. 11If the market opportunities for our product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer. Our ability to successfully identify patients and acquire a significant market share will be necessary for us to achieve profitability and growth

Risks Related to Our Financial Position and Growth Strategy

1. 12If we obtain a controlling interest in additional companies in the future, it could adversely affect our operating results and the value of our common stock, thereby disrupting our business
2. 13the outcome of any legal proceedings that may be instituted with respect to a potential acquisition, in-license or investment

Risks Related to the Development of Our Product Candidates

1. 14We may encounter substantial delays in clinical trials, or may not be able to conduct or complete clinical trials on the expected timelines, if at all
2. 15delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of product candidates that we may identify for use in clinical trials, or the inability to do any of the foregoing
3. 16Results of earlier studies or clinical trials may not be predictive of future clinical trial results, and initial studies or clinical trials may not establish an adequate safety or efficacy profile for our product candidates to justify proceeding to advanced clinical trials or an application for regulatory approval
4. 17We may encounter difficulties enrolling patients in clinical trials, and clinical development activities could thereby be delayed or otherwise adversely affected
5. 18If we have difficulty enrolling sufficient numbers of patients to conduct clinical trials as planned, we may need to delay or terminate ongoing or planned clinical trials, either of which would have an adverse effect on our business
6. 19Additionally, adverse developments in clinical trials of pharmaceutical and biopharmaceutical products conducted by others may cause the FDA or other regulatory oversight bodies to suspend or terminate our clinical trials, to change the requirements for approval of any of our product candidates
7. 20Certain of our product candidates are under development for the treatment of patient populations with significant comorbidities that may result in deaths or serious adverse or unacceptable side effects and require us to abandon or limit our clinical development activities
8. 21Preliminary, interim or topline data from our clinical trials that we announce or publish from time to time may change as more patient data become available or as additional analyses are conducted, and as the data are subject to audit and verification procedures that could result in material changes in the final data

Risks Related to Regulatory Review and Approval of our Product Candidates

1. 22If we are unable to obtain regulatory approval in one or more jurisdictions for any product candidates that we may identify and develop, our business will be substantially harmed
2. 23Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of product candidates that we may identify and pursue for their intended uses, which would prevent, delay or limit the scope of regulatory approval and commercialization
3. 24We conduct clinical trials for product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials
4. 25Even if we obtain FDA approval for any of our current product candidates in the United States, we may never obtain approval to commercialize any of these product candidates outside of the United States, which would limit our ability to realize their full market potential
5. 26Even though we may apply for orphan drug designation for our product candidates, we may not be able to obtain such designations or maintain the benefits associated with orphan drug status, including orphan drug marketing exclusivity
6. 27The FDA has granted rare pediatric disease designation to BBP-812 for the treatment of Canavan Disease. However, a marketing application for BBP-812 or any other product candidate, if approved, may not meet the eligibility criteria for a PRV
7. 28the NDA is approved for a different adult indication than the rare pediatric disease for which BBP-812 is designated (for example, if BBP-812 is approved for an indication based on specific genetic alterations that would be inclusive of, but not limited to, BBP-812)
8. 29Accelerated approval by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval
9. 30We may not elect or be able to take advantage of any expedited development or regulatory review and approval processes available to product candidates granted breakthrough therapy, fast track or regenerative medicine advanced therapy designation by the FDA
10. 31We may also seek RMAT designation for one or more of our product candidates. See the section titled, “Business — Government Regulation — Expedited Development and Review Programs” for additional information regarding RMAT designation
11. 32BBP-812 for the treatment of Canavan Disease
12. 33We may seek designation for our platform technology as a designated platform technology, but we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process
13. 34If we are unable to successfully validate, develop and obtain regulatory approval for companion diagnostic tests for our drug candidates that require or would commercially benefit from such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these product candidates
14. 35If approved, our investigational products regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway
15. 36If competitors are able to obtain marketing approval for biosimilars referencing any of our product candidates, our products may become subject to competition from such biosimilars, which would impair our ability to successfully commercialize and generate revenues from sales of such products
16. 37require a product recall
17. 38The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses
18. 39Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates

Risks Related to the Novel Nature of our Product Candidates

1. 40Certain of our product candidates, including our protein therapeutic and gene therapy product candidates, are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in our development or commercialization programs or otherwise harm our business
2. 41Certain of our product candidates are based on a novel adeno-associated virus (“AAV”) gene therapy technology with which there is limited clinical or regulatory experience to date, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval
3. 42Similarly, the EMA governs the approval of gene therapies in the European Union and may issue new guidelines concerning the development and marketing authorization for gene therapy products and require that we comply with these new guidelines

Risks Related to Our Reliance on Third Parties

1. 43We expect to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing
2. 44the possible termination or non-renewal of the agreement by the third party at a time that is costly or inconvenient for us
3. 45The drug substance and drug product for certain of our product candidates are currently acquired from single-source suppliers. The loss of these suppliers, or their failure to supply us with the drug substance or drug product, could materially and adversely affect our business
4. 46delays caused by supply issues may harm our reputation; and
5. 47If the contract manufacturing facilities on which we rely do not continue to meet regulatory requirements or are unable to meet our supply demands, our business will be harmed
6. 48Collaborative relationships with third parties could cause us to expend significant resources and incur substantial business risk with no assurance of financial return
7. 49We are parties to and may seek to enter into additional collaborations, licenses and other similar arrangements, and may not be successful in maintaining existing arrangements or entering into new ones, and even if we are, we may not realize the benefits of such relationships
8. 50a collaborator’s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings

Risks Related to Our Intellectual Property

1. 51Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of licenses granted to us by others, and the patent protection, prosecution and enforcement for some of our product candidates may be dependent on our licensors
2. 52the priority of invention of patented technology
3. 53Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts
4. 54Patent terms may be inadequate to protect our competitive position on product candidates for an adequate amount of time
5. 55If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business would be harmed
6. 56If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
7. 57We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful
8. 58We may be subject to claims challenging the inventorship of our patents and other intellectual property
9. 59Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court
10. 60We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers
11. 61Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
12. 62We may not be able to protect our intellectual property rights throughout the world
13. 63Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products
14. 64could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects

Risks Related to Our Business and Industry

1. 65Termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash management arrangements
2. 66Our corporate restructuring initiatives, including any associated workforce reductions or reorganizations, may not result in the full anticipated savings and may disrupt operations
3. 67We are highly dependent on the management, research and development, clinical, financial and business development expertise of our executive officers, our directors, our Management Committee as well as the other members of our scientific and clinical teams
4. 68Our reliance on a central team consisting of a limited number of employees who provide various administrative, research and development and other services across our organization, and on dedicated teams at the subsidiary level presents operational challenges that may adversely affect our business
5. 69We will need to expand our organization and we may experience difficulties in managing this growth, which could disrupt our operations
6. 70commercialize product candidates if approved, and compete effectively will depend, in part, on our ability to effectively manage any future growth
7. 71Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidates that we may develop
8. 72the inability to successfully commercialize our product candidates or medicines
9. 73Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
10. 74Our international operations may expose us to business, regulatory, political, operational, financial, tax, pricing and reimbursement and economic risks associated with doing business outside of the United States
11. 75certain expenses including, among others, expenses for travel, translation, and insurance; and
12. 76If we fail to maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired, which could negatively affect the price of our common stock
13. 77We do not expect that our disclosure controls or our internal control over financial reporting will prevent all errors and all fraud
14. 78Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information, and personal data
15. 79European data collection is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information

Risks Related to Our Indebtedness

1. 80We have incurred a significant amount of debt and may in the future incur additional indebtedness. Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our substantial debt
2. 81We have incurred indebtedness under our convertible senior notes and are party to a financing agreement that contains operating and financial covenants that may restrict our business and financing activities
3. 82• make certain investments
4. 83The conditional conversion feature of the Notes, if triggered, may adversely affect our financial condition and operating results

Risks Related to Our Need for Additional Capital

1. 84We may require substantial additional funding to achieve our business goals. If we are unable to obtain this funding when needed and on acceptable terms, we could be forced to delay, limit or terminate our product development and commercialization efforts
2. 85the costs of maintaining, expanding and protecting our intellectual property portfolio
3. 86Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to current product candidates or to any future product candidates on unfavorable terms
4. 87If we engage in other acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks
5. 88our inability to generate revenue from acquired intellectual property, technology and/or products sufficient to meet our objectives or even to offset the associated transaction and maintenance costs
6. 89respond to competitive pressures

Risks Related to Our Common Stock

1. 90The market price of our common stock has been and may be highly volatile, and purchasers of our common stock could incur substantial losses
2. 91continued increases in interest rates that increase the cost of our existing indebtedness any potential new indebtedness
3. 92We have in the past been and could be subject to securities class action litigation and other types of stockholder litigation
4. 93Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, would result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall
5. 94Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock
6. 95If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline
7. 96Our principal stockholders and certain members of our management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval
8. 97Provisions in our amended and restated certificate of incorporation and amended and restated bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management
9. 98These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management
10. 99Our amended and restated bylaws designate specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us
11. 100Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance
12. 101acts of war, armed conflicts and political or civil unrest, including volatile global economic conditions resulting from the conflicts in Ukraine and Israel and the Gaza Strip
13. 102Our future ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited
14. 103Changes in tax laws or regulations may adversely affect our financial condition and results of operations
15. 104We have never and do not currently intend to pay dividends on our common stock, and, consequently, our stockholders’ ability to achieve a return on their investment will depend on appreciation in the price of our common stock
16. 105We have incurred and will continue to incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives
17. 106Environmental, social and governance matters may impact our business and reputation
18. 107If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business
19. 108Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations
20. 109Significant political, trade, regulatory developments, and other circumstances beyond our control, could have a material adverse effect on our financial condition or results of operations
21. 110Our internal computer systems, or those used by our third-party collaborators, contractors or consultants, may fail or suffer cybersecurity incidents or breaches, which could result in a material disruption of our development programs and business operations
22. 111We or the third parties upon whom we depend may be adversely affected by climate change, earthquakes, outbreak of disease, or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster
23. 112Climate change or legal, regulatory or market measures to address climate change may negatively affect our business and results of operations
24. 113The increasing use of social media platforms presents new risks and challenges
25. 114Our business operations may subject us to disputes, claims and lawsuits, which may be costly and time-consuming and could materially and adversely impact our financial position and results of operations